Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The receptor activator of NF-kappaB (RANK) belongs to the neuregulin/tumor necrosis factor (TNF) receptor superfamily and is activated by RANK ligand (RANK-L), a homotrimeric, TNF-like cytokine. RANK is present on the surface of osteoclast cell precursors, where its interaction with RANK-L induces their terminal differentiation into osteoclasts, thus increasing bone breakdown. The secreted, soluble receptor osteoprotegerin (OPG) interrupts this activation by binding directly to RANK-L. Therefore, osteoclast maturation (and bone homeostasis) is regulated in vivo by OPG levels of expression. We have studied the assembly state and affinity of OPG for RANK-L by sedimentation analyses and surface plasmon resonance (Biacore). Full-length, homodimeric OPG binds to RANK-L with a KD of 10 nM. OPG is also a member of the TNF receptor superfamily and contains four disulfide-rich ligand-binding domains, yet lacks a transmembrane region separating the ligand-binding region from the two death domains, as observed for other receptor family members. We showed that dimerization of OPG results from noncovalent interactions mediated by the death domains and to a lesser extent by a C-terminal heparin-binding region. In contrast, a C-terminal intermolecular disulfide bond does not contribute to the formation or stability of OPG dimers. A truncate of osteoprotegerin, containing the ligand-binding domains but lacking the dimerization domains, bound RANK-L with a KD of approximately 3 microM, indicating that monomer oligomerization for the OPG provides an increase of 3 orders of magnitude in the affinity for RANK-L. Therefore, OPG dimer formation is required for the mechanism of inhibition of the RANK-L/RANK receptor interaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ability of OPG to suppress bone resorption and increase bone mass is related to its ability to bind via its TNF receptor domains to TNF domains within its natural ligand (17), now known as RANKL.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
In the citing paper
“to its target RANKL (17) and for osteoclast inhibition in cell culture studies (4,16).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
In the citing paper
“However, more recent analyses using analytical ultracentrifugation to more accurately identify monomer vs. homodimer forms revealed that the OPG homodimer had 1000-fold greater affinity for RANKL than the monomeric form (17).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling
Guex, N., & Peitsch, M. C. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150181505 · Cited by 11,241
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Enhanced genome annotation using structural profiles in the program 3D-PSSM 1 1Edited by J. Thornton
Kelley, L. A., MacCallum, R. M., & Sternberg, M. J. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3741 · Cited by 1,468
TNF? and the TNF receptor superfamily: Structure-function relationship(s)
Idriss, H. T., & Naismith, J. H. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<184::aid-jemt2>3.0.co;2-h · Cited by 1,183
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173
Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Luckow, V. A., Lee, S. C., Barry, G. F., & Olins, P. O. (1993) · Journal of Virology · doi:10.1128/jvi.67.8.4566-4579.1993 · Cited by 912
RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064753 · Cited by 819
The evolution and genetics of innate immunity
Kimbrell, D. A., & Beutler, B. (2001) · Nature Reviews Genetics · doi:10.1038/35066006 · Cited by 679
Regulatory mechanisms of osteoblast and osteoclast differentiation
Katagiri, T., & Takahashi, N. (2002) · Oral Diseases · doi:10.1034/j.1601-0825.2002.01829.x · Cited by 596
Fuller, K., Wong, B., Fox, S., Choi, Y., & Chambers, T. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.997 · Cited by 561
Oshannessy, D. J., Brighamburke, M., Soneson, K. K., Hensley, P., & Brooks, I. (1993) · Analytical Biochemistry · doi:10.1006/abio.1993.1355 · Cited by 548
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Romas, E., Gillespie, M. T., & Martin, T. J. (2002) · Bone · doi:10.1016/s8756-3282(01)00682-2 · Cited by 411
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363
Galibert, L., Tometsko, M. E., Anderson, D. M., Cosman, D., & Dougall, W. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.51.34120 · Cited by 331
Aubin, J. E., & Bonnelye, E. (2000) · Osteoporosis International · doi:10.1007/s001980070028 · Cited by 319
Insights into Programmed Cell Death through Structural Biology
Fesik, S. W. (2000) · Cell · doi:10.1016/s0092-8674(00)00119-7 · Cited by 312
Osteoporosis, genetics and hormones
Rizzoli, R., Bonjour, J., & Ferrari, S. (2001) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0260079 · Cited by 274
Philo, J. S. (2000) · Analytical Biochemistry · doi:10.1006/abio.2000.4480 · Cited by 247
Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor
Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., & Higashio, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5117 · Cited by 200
Kong, Y., Boyle, W. J., & Penninger, J. M. (1999) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1999.00815.x · Cited by 152
Schlöndorff, J., Lum, L., & Blobel, C. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010741200 · Cited by 130
Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.
Tomoyasu, A., Goto, M., Fujise, N., Mochizuki, S.-I., Yasuda, H., Morinaga, T., Tsuda, E., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8443 · Cited by 83
Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-Å Resolution
Ito, S., Wakabayashi, K., Ubukata, O., Hayashi, S., Okada, F., & Hata, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106525200 · Cited by 74
Sedimentation velocity spins a new weave for an old fabric
Stafford, W. F. (1997) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(97)80152-8 · Cited by 66
Yano, K., Shibata, O., Mizuno, A., Kobayashi, F., Higashio, K., Morinaga, T., & Tsuda, E. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5745 · Cited by 43
Willard, D. H., Chen, W., Barrett, G. B., Blackburn, K., Bynum, J. M., Consler, T. G., Hoffman, C. R., Horne, E., Iannone, M. A., Kadwell, S. H., et al. (2000) · Protein Expression and Purification · doi:10.1006/prep.2000.1278 · Cited by 26
Self-citationImmuno-PCR Assay for Homodimeric Osteoprotegerin
Furuya, D., Kaneko, R., Yagihashi, A., Endoh, T., Yajima, T., Kobayashi, D., Yano, K., Tsuda, E., & Watanabe, N. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.8.1475 · Cited by 16
Merewether, L. A., Le, J. C., Jones, M. D., Lee, R. G., Shimamoto, G. T., & Lu, H. S. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1636 · Cited by 15
Research works printed but not linked: 2
- South-Paul, 2001, Am. Family Physician, 63, 897
- Carolino, 1998, Am. Family Physician, 57, 1293
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Multiple Genetic Loci for Bone Mineral Density and Fractures
Styrkarsdottir, U., Halldorsson, B. V., Gretarsdottir, S., Gudbjartsson, D. F., Walters, G. B., Ingvarsson, T., Jonsdottir, T., Saemundsdottir, J., Center, J. R., Nguyen, T. V., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801197 · Cited by 629
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédini, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 170
Osteoprotegerin: Multiple partners for multiple functions
Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153
“However, it has been shown that the OPG homodimer exhibits higher affinity for the RANKL homotrimer [6,25].”
Background
Metadata
- Authors
- Schneeweis, L. A., Willard, D., & Milla, M. E.
- Affiliations
- University of Pennsylvania (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Schneeweis, Lumelle A.
- Milla, Marcos E.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 280
- Issue
- 50
- Pages
- 41155-41164
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2000736649
- Cited by
- 116
- References
- 35
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 7
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5418 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r21dk067831-01)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK067831)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- osteoprotegerin, RANK ligand, RANK, TNF receptor superfamily, receptor dimerization, ligand binding affinity, death domain, disulfide bonds, osteoclastogenesis, bone homeostasis
- MeSH terms
- Animals, Antibody Affinity, Biological Assay, Carrier Proteins, Cell Differentiation, Cell Membrane, Circular Dichroism, Disulfides, Escherichia coli, Genetic Vectors, Glycoproteins, Heparin, Humans, Insecta, Kinetics, Ligands, Membrane Glycoproteins, Models, Chemical, Mutation, Osteoclasts, Protein Binding, Proteins, Time Factors, Viruses, Cytokines, Protein Structure, Tertiary, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Dimerization, Surface Plasmon Resonance, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.